Loading data for RYTM — first visit, this takes a few seconds.

알림

Rhythm Pharmaceuticals In... (RYTM)

NasdaqGM: RYTM · 실시간 가격 · USD

112.84

-2.64 (-2.29%)

종가 기준: Aug 11, 2026, 8:00 PM

112.99

+0.13%

프리마켓: 7:30 AM

-2.29% (1D)

데이터 없음

매수호가	77.4
시가총액	7.77B
매출 (ttm)	239.92M
순이익 (ttm)	-210.22M
베타	1.97
EPS (ttm)	-3.12
P/E (ttm)	n/a
선행 P/E	-184.56
P/B (ttm)	75.43
P/S (ttm)	32.26
Earnings Date	Nov 3, 2026

매도호가	140.85
거래량	728,454
평균 거래량 (20일)	791,675
시가	113.17
전일 종가	115.48
일중 범위	112.51 - 117.48
52주 범위	74.50 - 122.20
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

RYTM 소개

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syn...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 9, 2017

직원 수 414

상장 거래소 NasdaqGM

티커 RYTM

웹사이트 https://rhythmtx.com

전체 기업 정보

재무 실적

2025년 Rhythm Pharmaceuticals의 매출은 189.76M로, 전년 130.13M 대비 45.83% 증가했습니다. 순이익은 -196.54M로, -24.58% 감소했습니다.

재무제표

어닝 서프라이즈

Rhythm Pharmaceuticals가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $71.25M 예상치 하회 $0, 및 46.91% 전년 대비 성장.

EPS -0.73 예상치 상회 0.10, 및 2.67% 전년 대비 성장.

다음 실적 발표

Rhythm Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 3, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Motley Fool

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

IMCIVREE revenue surged 19% sequentially as HO patient adoption accelerated post-approval.

2주 전 · Moby

Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Moby summary of Rhythm Pharmaceuticals, Inc.'s Q2 2026 earnings call

2주 전 · MarketBeat

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company ci...

2주 전 · Zacks

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3주 전 · Simply Wall St.

Could Anticipated Q2 Earnings Beat Amid Weaker Profitability Reframe Rhythm Pharmaceuticals’ Growth Story (RYTM)?

In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a pote...

2 페이지 중 1